Scholars Central

Research articlePublished 2013

A Pilot Study- Neoadjuvant Chemotherapy with Gemcitabine and S1 in Patients with Resectable and Borderline Resectable Pancreatic Cancer

Authors: Akira Matsushita, Yoshiharu Nakamura, Hiroki Sumiyoshi, Takayuki Aimoto, Tadashi Yokoyama, Eiji Uchida

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Introduction: Combination chemotherapy with gemcitabine and S-1 (GS) in metastatic advanced pancreatic cancer patients is superior to gemcitabine alone in response rate and progression free survival. We investigated this combination chemotherapy as neoadjuvant therapy for resectable and borderline resectable pancreatic cancer. Methods: Eleven patients with resectable or borderline resectable pancreatic cancer were administered to neoadjuvant chemotherapy with GS (NeoGS) from June 2011 to March 2013 at Nippon Medical School, and shortterm outcome was evaluated. Results: The median age was 69.1 years. According to NCCN criteria, 6 patients were resectable diseases and 5 were borderline resectable diseases. All patients received Neo GS with a median cycle of 3.5 (range: 2-11). No serious adverse events including death or life-threatening complications happened. Grade 3 or 4 chemotherapyrelated toxicities included neutropenia (81.8%), anemia (18.2%), thrombocytopenia (18.2%), and febrile neutropenia (9.1%). Other non-hematological toxicities with grade 1 or 2 were anorexia (36.4%), constipation (36%), nausea (27.3%), diarrhea (18.2%), dysgeusia (9.1%), and stomatitis (9.1%). Radiologically, partial response was documented in 3 patients (27.3%), and the remaining 8 patients (72.7%) had stable disease. All patients underwent pancreatic resection with lymphadenectomy. An R0 resection was achieved in 10 of 11 (90.9%), and negative nodal involvement (N0) was found in 6 (54.5%). Pathologically, all specimens showed at least Evans grade I, while eight of eleven (72.7%) had Evans grade IIa. There was no mortality and severe morbidity including clinically relevant pancreatic fistula. All patients received adjuvant chemotherapy with either gemcitabine or S1. Conclusion: This pilot study suggests NeoGS is feasible in patients with resectable and borderline resectable pancreatic cancer and may be associated with a high R0 resection rate and a low lymph node metastasis rate, suggesting that further phase 2 and 3 trials are warranted.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Carcinogenesis & Mutagenesis.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Carcinogenesis & Mutagenesis
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Akira Matsushita”
  • BylineArticles whose byline prints “Yoshiharu Nakamura”
  • BylineArticles whose byline prints “Hiroki Sumiyoshi”
  • BylineArticles whose byline prints “Takayuki Aimoto”
  • BylineArticles whose byline prints “Tadashi Yokoyama”
  • BylineArticles whose byline prints “Eiji Uchida”